Literature DB >> 23631943

Hand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012.

Jiratchaya Puenpa1, Thaweesak Chieochansin, Piyada Linsuwanon, Sumeth Korkong, Siwanat Thongkomplew, Preyaporn Vichaiwattana, Apiradee Theamboonlers, Yong Poovorawan.   

Abstract

In Thailand, hand, foot, and mouth disease (HFMD) is usually caused by enterovirus 71 or coxsackievirus A16. To determine the cause of a large outbreak of HFMD in Thailand during June-August 2012, we examined patient specimens. Coxsackievirus A6 was the causative agent. To improve prevention and control, causes of HFMD should be monitored.

Entities:  

Keywords:  hand, foot, and mouth disease; herpangina, enterovirus 71, coxsackievirus A6, coxsackievirus A16, Thailand, viruses

Mesh:

Substances:

Year:  2013        PMID: 23631943      PMCID: PMC3647428          DOI: 10.3201/eid1904.121666

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Coxsackievirus A6 (CAV6) is 1 of 10 genotypes within the family Picornaviridae, genus Enterovirus, species Human enterovirus A. Other genotypes include coxsackievirus A16 (CAV16) and enterovirus 71 (EV71). Although CAV6 is commonly associated with hand, foot, and mouth disease (HFMD) and herpangina (,), it has not been of concern until the recent global outbreaks of HFMD (–). In Thailand, the viruses predominately associated with HFMD have been EV71 and CAV16 (,); to our knowledge, CAV6 has not been implicated. In 2012, extensive outbreaks of HFMD occurred in Thailand. To determine the pattern, causative agents, and clinical manifestations of HFMD in this 2012 outbreak, we analyzed specimens from patients. This study was approved by the institutional review board of the Faculty of Medicine, Chulalongkorn University; the requirement for written informed consent was waived because the samples were analyzed anonymously.

The Study

In Thailand, HFMD usually occurs during the rainy season (June–August); average incidence during 2007–2011 was 20.2 cases per 100,000 population (,). In 2012, an extensive outbreak of HFMD occurred; the incidence rate was 3-fold higher than the average incidence rate of 58.15 cases per 100,000 population or >36.000 cases; the 2012 outbreak included 2 fatal cases of EV71 encephalitis (). In this outbreak, 2 clinical patterns were observed, and 2 case definitions were applied. Suspected HFMD cases were defined as painful blisters in the oropharynx and blisters on the palms, soles, knees, elbows, and/or buttocks. Suspected herpangina cases were defined as painful blisters in the mouth only, predominantly on the soft palate. Suspected HFMD and herpangina cases were virologically confirmed if samples were positive for viral RNA by nested PCR. During January–October 2012, a total of 847 samples were collected from 825 patients with suspected cases. Among those 825 patients, the diagnosis was HFMD for 672 (81.4%) and herpangina for 153 (18.6%). Patients’ ages ranged from 1 month to 38 years. The samples were collected from hospitalized patients and outpatients who had a clinical diagnosis of HFMD or herpangina and who came from different parts of Thailand: Bangkok, 566 cases; Khonkaen, 252 cases; Suphanburi, 4 cases; and Saraburi, Rayong, and Chantaburi, 1 case each (Figure 1). Of the 847 samples, 695 were rectal swabs, 73 fecal, 39 throat swabs, 20 serum, 9 vesicle fluid, 7 nasal swabs, 3 cerebrospinal fluid, and 1 saliva. All samples, other than stool samples, were collected in virus transport media modified according to recommendations by the World Health Organization (). Fecal samples were diluted 1:10 with phosphate-buffered saline and centrifuged, and the supernatant was collected for testing. Viral RNA was extracted from 200-μL samples by using the Viral Nucleic Acid Extraction Kit (RBC Bioscience, Taipei, Taiwan) according to the manufacturer’s instructions. cDNA was synthesized by using the ImProm-II Reverse Transcription System (Promega, Madison, WI, USA) with random hexamers as primers according to the manufacturer’s recommendation (First BASE Laboratories, Selangor Darul Ehsan, Malaysia).
Figure 1

Location of sample collection sites during outbreak of hand, foot, and mouth disease, Thailand, January–October 2012.

Location of sample collection sites during outbreak of hand, foot, and mouth disease, Thailand, January–October 2012. To identify enteroviruses, we performed 3 separate PCRs. The first PCR, which could detect most enteroviruses, was used to screen for panenterovirus. The 5′ untranslated region of the viruses was amplified by nested PCR as described (). The second PCR was selective for EV71 and CAV16; the primers and reaction conditions were identical to those used in a previous study (). The third PCR, for CAV6 detection, used primers designed to amplify the viral protein (VP) 1 gene by seminested PCR with CU-EVF2632 (5′-TGTGTGATGAATCGAAACGGGGT-3′) and CU-EVR3288 (5′-TGCAGTGTTAGTTATTGT TTGGCT-3′) as first-round primers and CU-EVR3053 (5′-GGGTAACCATCATAAAACCACTG-3′) as a reverse primer for the second round. The expected 420-bp PCR product was examined under UV light after being resolved in 2% agarose gel electrophoresis and subsequently stained with ethidium bromide. Most samples were collected during the rainy season, from the end of June through early August 2012 (weeks 25–32), which accounted for 83.1% of all reported cases. Altogether, enterovirus results were positive for 459 (68.3%) HFMD and 101 (66.0%) herpangina patients (Figure 2),
Figure 2

Weekly number of reported suspected cases of hand, foot, and mouth disease and herpangina during outbreak, Thailand, 2012. EV, enterovirus; CA6, coxsackievirus 6; CA16, coxsackievirus 16; EV71, enterovirus 71.

Weekly number of reported suspected cases of hand, foot, and mouth disease and herpangina during outbreak, Thailand, 2012. EV, enterovirus; CA6, coxsackievirus 6; CA16, coxsackievirus 16; EV71, enterovirus 71. Of note, 93.1% of patients were <5 years of age. A high proportion of cases was found among children 1, 2, and 3 years of age and accounted for 68.4% of HFMD cases and 64.2% of herpangina cases (Technical Appendix Figure 1). Of the 672 HFMD cases, 221 (32.9%) were caused by CAV6, 62 (9.2%) by EV71, 62 (9.2%) by CAV16, and 114 (17.0%) by untyped enteroviruses. Of the herpangina cases, 13.7% were caused by CAV6 and 1.3% by CAV16. Moreover, samples from 51.0% of patients with herpangina were positive for an untyped enterovirus (Table).
Table

Causative agents identified during hand, foot, and mouth disease outbreak, Thailand, 2012

VirusNo. (%) cases
Hand, foot, and mouth diseaseHerpangina
Coxsackievirus A6221 (32.9)21 (13.7)
Coxsackievirus A1662 (9.2)2 (1.3)
Enterovirus A7162 (9.2)0
Panenterovirus only114 (17.0)78 (51.0)
None detected213 (31.7)52 (34.0)
Total672153
Generally, the clinical manifestations of HFMD were fever; drooling, and refusal to eat (among young children); painful lesions in the mouth, especially on the soft palate (Technical Appendix Figure 2, panel A); and vesicular rashes on the palms and feet (Technical Appendix Figure 2, panels B, C). For patients affected by this outbreak, physicians from reporting sites reported anecdotally that they observed more severe skin manifestations than usual, especially on the buttocks and perianal area (Technical Appendix Figure 2, panel D), knees, and elbows. Two cases with neurologic involvement (convulsion, altered consciousness) were caused by EV71 and were treated with intravenous immunoglobulin. No patients died. Direct sequencing was performed on the VP1 region of 143 randomly selected CAV6-positive samples. The sequences were submitted to GenBank under accession nos. JX556422–JX556564. The VP1 nucleotide sequences of CAV6 were aligned with the reference sequences by using ClustalW in the BioEdit program version 7.0.9.0 (www.mbio.ncsu.edu/BioEdit/bioedit.html). A phylogenetic tree was constructed with MEGA software, version 5.0, by applying the maximum-likelihood method and using the Kimura 2-parameter model, in which 1,000 replications were selected for bootstrapping () (Technical Appendix Figure 3). The sequences of EV71 strain BrCr (accession no. U22521) and CAV16 strain G10 (accession no. U05876) were used as outgroups in the phylogenetic analysis. The relationship between the CAV6 characterized in this study and the prototype strain (Gdula) was investigated by phylogenetic analysis of partial VP1 sequences. All CAV6 clustered in the same lineage and with the reference strain CAV6 (Gdula); nucleotide homologies among these strains were 81.4%–84.7%.

Conclusions

Although the positive samples collected during January–October 2012 were mostly from patients in Bangkok and Khonkaen, they partially represented the HFMD and herpangina cases in Thailand’s 30,000-case outbreak. Virus prevalence in Thailand was highest in HFMD and herpangina patients 1–3 years of age (Technical Appendix Figure 1). For this seasonal outbreak, the most common causative agent was CAV6. All CAV6 strains shared an isolated cluster and had high similarity, as shown in the phylogenetic analysis of VP1 region. Although CAV6 has been a predominant emerging pathogen since 2012, no patients infected with CAV6 died. According to the study conducted during 2008–2011 EV71 and CAV16 were the main pathogens contributing to the disease (). However, we found a different main pathogen: CAV6. For prevention and control of future outbreaks, the causes of HFMD should be monitored.

Technical Appendix

Age distribution of patients with reported cases of hand, foot, and mouth disease and herpangina, Thailand, January–October 2012, clinical manifestations in children with coxsackievirus A6 infection, and phylogenetic analysis of coxsackievirus A6.
  10 in total

1.  Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study.

Authors:  A Mirand; C Henquell; C Archimbaud; S Ughetto; D Antona; J-L Bailly; H Peigue-Lafeuille
Journal:  Clin Microbiol Infect       Date:  2012-03-08       Impact factor: 8.067

2.  Prevalence of coxsackievirus A5, A6, and A10 in patients with herpangina in Aichi Prefecture, 2005.

Authors:  Teruo Yamashita; Miyabi Ito; Akiko Taniguchi; Kennji Sakae
Journal:  Jpn J Infect Dis       Date:  2005-12       Impact factor: 1.362

3.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.

Authors:  Koichiro Tamura; Daniel Peterson; Nicholas Peterson; Glen Stecher; Masatoshi Nei; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2011-05-04       Impact factor: 16.240

4.  Clinical and molecular characterization of hand-foot-and-mouth disease in Thailand, 2008-2009.

Authors:  Susheera Chatproedprai; Apiradee Theanboonlers; Sumeth Korkong; Chittima Thongmee; Siriwan Wananukul; Yong Poovorawan
Journal:  Jpn J Infect Dis       Date:  2010-07       Impact factor: 1.362

5.  Notes from the field: severe hand, foot, and mouth disease associated with coxsackievirus A6 - Alabama, Connecticut, California, and Nevada, November 2011-February 2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-03-30       Impact factor: 17.586

6.  Molecular characterization and complete genome analysis of human enterovirus 71 and coxsackievirus A16 from children with hand, foot and mouth disease in Thailand during 2008-2011.

Authors:  Jiratchaya Puenpa; Apiradee Theamboonlers; Sumeth Korkong; Piyada Linsuwanon; Chittima Thongmee; Susheera Chatproedprai; Yong Poovorawan
Journal:  Arch Virol       Date:  2011-09-07       Impact factor: 2.574

7.  Hand, foot, and mouth disease caused by coxsackievirus a6.

Authors:  Kelly Flett; Ilan Youngster; Jennifer Huang; Alexander McAdam; Thomas J Sandora; Marcus Rennick; Sandra Smole; Shannon L Rogers; W Allan Nix; M Steven Oberste; Stephen Gellis; Asim A Ahmed
Journal:  Emerg Infect Dis       Date:  2012-10       Impact factor: 6.883

8.  Hand, foot, and mouth disease caused by coxsackievirus A6, Japan, 2011.

Authors:  Tsuguto Fujimoto; Setsuko Iizuka; Miki Enomoto; Katsuhiko Abe; Kazuyo Yamashita; Nozomu Hanaoka; Nobuhiko Okabe; Hiromu Yoshida; Yoshinori Yasui; Masaaki Kobayashi; Yoshiki Fujii; Hiroko Tanaka; Miwako Yamamoto; Hiroyuki Shimizu
Journal:  Emerg Infect Dis       Date:  2012-02       Impact factor: 6.883

9.  Coxsackievirus A6 and hand, foot, and mouth disease, Finland.

Authors:  Riikka Osterback; Tytti Vuorinen; Mervi Linna; Petri Susi; Timo Hyypiä; Matti Waris
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

10.  Detection of non-polio enteroviruses in Hungary 2000-2008 and molecular epidemiology of enterovirus 71, coxsackievirus A16, and echovirus 30.

Authors:  Beatrix Kapusinszky; Katalin N Szomor; Agnes Farkas; Mária Takács; György Berencsi
Journal:  Virus Genes       Date:  2010-01-01       Impact factor: 2.198

  10 in total
  61 in total

Review 1.  Is a multivalent hand, foot, and mouth disease vaccine feasible?

Authors:  Michel Klein; Pele Chong
Journal:  Hum Vaccin Immunother       Date:  2015-05-26       Impact factor: 3.452

Review 2.  Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy.

Authors:  S Aswathyraj; G Arunkumar; E K Alidjinou; D Hober
Journal:  Med Microbiol Immunol       Date:  2016-07-12       Impact factor: 3.402

3.  Molecular epidemiology of coxsackievirus A6 associated with outbreaks of hand, foot, and mouth disease in Tianjin, China, in 2013.

Authors:  Xiaojuan Tan; Li Li; Baomin Zhang; Jaume Jorba; Xu Su; Tianjiao Ji; Dongjing Yang; Likun Lv; Jiameng Li; Wenbo Xu
Journal:  Arch Virol       Date:  2015-02-15       Impact factor: 2.574

4.  High prevalence of coxsackievirus A2 in children with herpangina in Thailand in 2015.

Authors:  Jira Chansaenroj; Chompoonut Auphimai; Jiratchaya Puenpa; John Mauleekoonphairoj; Nasamon Wanlapakorn; Viboonsuk Vuthitanachot; Sompong Vongpunsawad; Yong Poovorawan
Journal:  Virusdisease       Date:  2017-02-14

5.  Divergent Pathogenic Properties of Circulating Coxsackievirus A6 Associated with Emerging Hand, Foot, and Mouth Disease.

Authors:  Shao-Hua Wang; Ao Wang; Pan-Pan Liu; Wen-Yan Zhang; Juan Du; Shuang Xu; Guan-Chen Liu; Bai-Song Zheng; Chen Huan; Ke Zhao; Xiao-Fang Yu
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

6.  A Neonatal Murine Model of Coxsackievirus A6 Infection for Evaluation of Antiviral and Vaccine Efficacy.

Authors:  Zhenjie Zhang; Zhaopeng Dong; Qingjuan Wei; Michael J Carr; Juan Li; Shujun Ding; Yigang Tong; Dong Li; Weifeng Shi
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

7.  Clinical Features and Peripheral Blood T Lymphocyte Subsets in Hand, Foot, and Mouth Disease According to Different Pathogens.

Authors:  Jian-Fang Zhou; Zhi-Yong Chen; Shan-Ming Yang; Jia-Zhen Chen; Ling-Ye Zhou; Ya-Fen Wang; Gang Wang; Xia-Jian Yu; Wen-Hong Zhang
Journal:  Indian J Pediatr       Date:  2016-07-28       Impact factor: 1.967

8.  Complete genome sequence analysis of enterovirus 71 isolated from children with hand, foot, and mouth disease in Thailand, 2012-2014.

Authors:  John Mauleekoonphairoj; Sompong Vongpunsawad; Jiratchaya Puenpa; Sumeth Korkong; Yong Poovorawan
Journal:  Virus Genes       Date:  2015-08-25       Impact factor: 2.332

9.  Development and evaluation of a non-ribosomal random PCR and next-generation sequencing based assay for detection and sequencing of hand, foot and mouth disease pathogens.

Authors:  Anh To Nguyen; Thanh Tan Tran; Van Minh Tu Hoang; Ngoc My Nghiem; Nhu Nguyen Truc Le; Thanh Thi My Le; Qui Tu Phan; Khanh Huu Truong; Nhan Nguyen Thanh Le; Viet Lu Ho; Viet Chau Do; Tuan Manh Ha; Hung Thanh Nguyen; Chau Van Vinh Nguyen; Guy Thwaites; H Rogier van Doorn; Tan Van Le
Journal:  Virol J       Date:  2016-07-07       Impact factor: 4.099

10.  Molecular Epidemiological Study of Hand, Foot, and Mouth Disease in a Kindergarten-Based Setting in Bangkok, Thailand.

Authors:  Nipa Thammasonthijarern; Nathamon Kosoltanapiwat; Warisa Nuprasert; Pichamon Sittikul; Pimolpachr Sriburin; Wirichada Pan-Ngum; Pannamas Maneekan; Somboon Hataiyusuk; Weerawan Hattasingh; Janjira Thaipadungpanit; Supawat Chatchen
Journal:  Pathogens       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.